Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisinopril add-on in extracapillary glomerulonephritis
2015-003884-12Phase 2Terminated
- Sponsor
- Papa Giovanni XXIII Hospital
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of lisinopril in crescentic glomerulonephritis (RPGN) and proliferative glomerulonephritis (2 arms), sponsored by Papa Giovanni XXIII Hospital. Primary endpoint: Extent of extracapillary proliferation. Started Jan 2021; status: terminated.
02
Drugs
lisinopril
03
Conditions
crescentic glomerulonephritis (RPGN)proliferative glomerulonephritis
Beyond the preview
Go deeper on 2015-003884-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003884-12.